Great Lakes Retirement Inc. Has $1.36 Million Position in Sanofi (NASDAQ:SNY)

Great Lakes Retirement Inc. grew its position in Sanofi (NASDAQ:SNY) by 1.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,263 shares of the company’s stock after buying an additional 424 shares during the quarter. Great Lakes Retirement Inc.’s holdings in Sanofi were worth $1,356,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in SNY. Fairfield Bush & CO. acquired a new position in shares of Sanofi in the 1st quarter valued at approximately $26,000. Bank of New York Mellon Corp grew its holdings in shares of Sanofi by 31.3% during the 1st quarter. Bank of New York Mellon Corp now owns 440,646 shares of the company’s stock valued at $22,623,000 after purchasing an additional 105,046 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Sanofi by 12.9% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 24,613 shares of the company’s stock valued at $1,264,000 after purchasing an additional 2,805 shares during the last quarter. Yousif Capital Management LLC grew its holdings in shares of Sanofi by 45.2% during the 1st quarter. Yousif Capital Management LLC now owns 42,041 shares of the company’s stock valued at $2,158,000 after purchasing an additional 13,095 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Sanofi by 0.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 300,009 shares of the company’s stock valued at $15,402,000 after purchasing an additional 1,391 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Price Performance

Shares of SNY stock traded down $0.21 during trading hours on Wednesday, hitting $49.54. 2,529,821 shares of the company’s stock were exchanged, compared to its average volume of 1,846,272. The company has a market capitalization of $125.32 billion, a PE ratio of 21.06, a PEG ratio of 1.83 and a beta of 0.61. Sanofi has a 12-month low of $42.63 and a 12-month high of $57.82. The business’s 50 day simple moving average is $48.23 and its 200-day simple moving average is $49.42. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). The business had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%. On average, equities research analysts anticipate that Sanofi will post 4.19 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. lowered shares of Sanofi from an “overweight” rating to a “neutral” rating in a report on Tuesday, December 5th. TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Finally, Morgan Stanley started coverage on shares of Sanofi in a report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.